Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$42.52M
Enterprise Value$12.77M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)$643.00K
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.80
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSharp revenue increase in 2025 (~$8.5M vs ~$0.2M in 2024) signals improved commercial or partner traction and partial validation of the development portfolio. If sustained or repeatable, this can increase non-dilutive funding, support continued R&D, and reduce binary clinical-stage investment risk over the next several quarters.
Low Absolute DebtModest absolute debt (~$0.6M in 2025) limits interest expense and reduces near-term default probability compared with highly leveraged peers. Low borrowing levels preserve capacity to seek equity or partnership funding and give management flexibility while clinical programs advance.
Focused Oncology PipelineA concentrated strategy on targeted small-molecule and precision oncology candidates focuses R&D capital on genetically defined cancers. That specialization can create durable competitive advantages, clearer partner/ licensing appeal, and the potential for high-margin products if clinical milestones are achieved.
Bears Say
Persistent Cash BurnOperating and free cash flow were both roughly -$10.4M in 2025, reflecting persistent cash burn despite improvement from 2024. Ongoing negative cash generation creates reliance on external financing, heightens dilution risk, and limits the company's ability to self-fund multi-year clinical development programs.
Negative Shareholders' EquityEquity deteriorated to about -$3.2M in 2025 from +$4.9M in 2024, signaling a material weakening in balance-sheet strength. Negative equity constrains financing options, raises counterparty and investor concerns, and increases the likelihood of dilutive capital raises or restructuring to restore solvency.
Nasdaq Listing NoncomplianceA June Nasdaq notice for failure to meet minimum market value requirements is a structural regulatory/listing risk. Potential remediation, suspension, or delisting threats can impair stock liquidity, complicate capital raises, and materially affect investor access and confidence until resolved.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $42.52M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 78 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
288.40%
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
48.22% Insiders
0.03% Mutual Funds
― Other Institutional Investors
51.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---